Monika Serke

K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways

Matthias Scheffler, Michaela A. Ihle, Rebecca Hein et al. · Journal of Thoracic Oncology · 2018 · 259 citations · Full text

Medicine, Genetics, Oncology +17

Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease

Petra Hoffknecht, Amanda Tufman, Thomas Wehler et al. · Journal of Thoracic Oncology · 2014 · 252 citations · Full text

Medicine, Oncology, Pharmacology +16

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

Anna Kron, Christina Alidousty, Matthias Scheffler et al. · Annals of Oncology · 2018 · 211 citations · Full text

Medicine, Molecular Genetics, Oncology +17

<i>MET</i> Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung

Hans‐Ulrich Schildhaus, Anne M. Schultheis, Josef Rüschoff et al. · Clinical Cancer Research · 2014 · 189 citations

Medicine, Genetics, Oncology +17

Phase III Study of Second-Line Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Weekly Compared With 3-Weekly Docetaxel

Wolfgang Schuette, S. Nagel, Thomas Blankenburg et al. · Journal of Clinical Oncology · 2005 · 181 citations

Medicine, Oncology, Pharmacology +17